Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269241 | 0.81 | ROCK2 (0.50) | KDM4EALDH1A1TSHRUSP2CYP1A2 | |
| SCHEMBL1360345 | 0.78 | PIK3CA (0.58) | KDM4EPIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL1568985 | 0.76 | KDM4E (0.48) | KDM4EPIK3CAPIK3CDPIK3CBHTR2A | |
| SCHEMBL19414284 | 0.75 | HTR2A (0.58) | KDM4EPIK3CAPIK3CDPIK3CBHTR2A | |
| SCHEMBL336705 | 0.74 | KDM4E (0.49) | KDM4EPIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL1286633 | 0.74 | PIK3CA (0.50) | KDM4EPIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL30677292 | 0.74 | KDM4E (0.49) | KDM4EPIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL3722451 | 0.73 | PIK3CA (0.49) | KDM4EPIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL30604932 | 0.73 | KMT2A (0.53) | KDM4EPIK3CAPIK3CDPIK3CBALDH1A1 | |
| SCHEMBL13828371 | 0.73 | HTR2A (0.66) | PIK3CAPIK3CDPIK3CBHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491036-B1 | 1,4-substituted 6-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidine derivatives as phosphoinositide-3-kinase inhibitors (PI3K) for treating allergies and asthma | MERCK PATENT GMBH (DE) | 2017-07-19 | — | — | EP | disclosed |
| EP-2382207-B1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING CO LLC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912178-B2 | mTOR selective kinase inhibitors | Xcovery Holdings Company, LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586582-B2 | PI3K/mTOR kinase inhibitors | XCOVERY HOLDING COMPANY, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2571884-A2 | MTOR SELECTIVE KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2571884-A2 | MTOR SELECTIVE KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2011146594-A2 | MTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146594-A2 | MTOR SELECTIVE KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | XCOVERY HOLDING COMPANY, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2382207-A2 | PI3K/MTOR KINASE INHIBITORS | Xcovery Holding Company LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010056320-A3 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056320-A2 | PI3K/MTOR KINASE INHIBITORS | TYROGENEX, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072481-A1 | mTOR SELECTIVE KINASE INHIBITORS | MTOR, ULK1, ULK2 | KDM4E 550/4885PIK3CA 69/4885PIK3CD 119/4885 |
| US-20110281857-A1 | PI3K/MTOR KINASE INHIBITORS | MTOR, PIK3CA, PI4KA | KDM4E 1150/4885PIK3CA 2/4885PIK3CD 5/4885 |
| US-20080234262-A1 | PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS | MTOR, PIK3CA, PDPK1 | KDM4E 2732/4885PIK3CA 2/4885PIK3CD 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.